Lotus Pharmaceutical Co (美時化學製藥) has received approval from Japan’s Pharmaceuticals and Medical Devices Agency for its generic version of blood cancer drug Revlimid (lenalidomide), boosting its shares by as much as 3.54 percent in early Taipei trading yesterday.
The approval was for 2.5mg and 5mg capsules of lenalidomide, which it jointly developed with Japan’s Fuji Pharma Corp, Lotus Pharmaceutical said in a regulatory filing on Tuesday.
Lotus Pharmaceutical was responsible for developing the lenalidomide formula — the company’s first high-value generic product in Japan, while Fuji Pharma ran local bioequivalence studies of the drug.
Photo: Reuters
With the approval, Lotus Pharmaceutical is to supply the finished product to Fuji Pharma for commercialization in Japan. The companies expect to launch the product in Japan this year.
Sales of Revlimid in Japan totaled about US$282 million last year, Lotus Pharmaceutical said, citing data from life sciences researcher Iqvia Institute.
As of the second quarter, only Osaka, Japan-based Sawai Pharmaceutical Co had obtained agency approval for lenalidomide, but its generic product has not yet been marketed in the Japanese market, Lotus Pharmaceutical said.
“Lotus and Fuji are among the first to market their product in Japan and gain a good market share there,” Capital Investment Management Corp (群益投顧) said in a note yesterday. “Lotus received 16 approvals for its generic products worldwide in the second quarter, which is a remarkable achievement and will gradually contribute to its revenue and royalty income in the future.”
Lotus Pharmaceutical shares surged in early morning trading yesterday before retreating to close up 1.71 percent at NT$268.
Capital Investment gave Lotus Pharmaceutical a “buy” rating with a 12-month target price of NT$295.
Lotus Pharma’s net profit more than tripled to NT$1.27 billion (US$39.82 million) in the second quarter, up 286 percent from NT$327.67 million in the same period last year, the company said on Tuesday.
That translated into earnings per share (EPS) of NT$4.85, the best second-quarter performance in its history.
In the first half of the year, EPS totaled NT$9.43, up 217 percent year-on-year, it said.
Lotus Pharma’s cumulative revenue in the first seven months totaled NT$11.25 billion, up 58.16 percent from the same period last year, company data showed.
With better business prospects, the company projected annual revenue growth of 13 to 15 percent for this year, higher than its previous estimate of 7 to 10 percent, while gross margin is expected to reach 55 percent, compared with 50 percent in its earlier forecast.
HORMUZ ISSUE: The US president said he expected crude prices to drop at the end of the war, which he called a ‘minor excursion’ that could continue ‘for a little while’ The United Arab Emirates (UAE) and Kuwait started reducing oil production, as the near-closure of the crucial Strait of Hormuz ripples through energy markets and affects global supply. Abu Dhabi National Oil Co (ADNOC) is “managing offshore production levels to address storage requirements,” the company said in a statement, without giving details. Kuwait Petroleum Corp said it was lowering production at its oil fields and refineries after “Iranian threats against safe passage of ships through the Strait of Hormuz.” The war in the Middle East has all but closed Hormuz, the narrow waterway linking the Persian Gulf to the open seas,
RATIONING: The proposal would give the Trump administration ample leverage to negotiate investments in the US as it decides how many chips to give each country US officials are debating a new regulatory framework for exporting artificial intelligence (AI) chips and are considering requiring foreign nations to invest in US AI data centers or security guarantees as a condition for granting exports of 200,000 chips or more, according to a document seen by Reuters. The rules are not yet final and could change. They would be the first attempt to regulate the flow of AI chips to US allies and partners since US President Donald Trump’s administration said it rescinded its predecessor’s so-called AI diffusion rules. Those rules sought to keep a significant amount of AI
Apple Inc increased iPhone production in India by about 53 percent last year and now makes a quarter of its marquee devices there, reflecting the US company’s efforts to avoid tariffs on China. The company assembled about 55 million iPhones in India last year, up from 36 million a year earlier, people familiar with the matter said, asking not to be named because the numbers aren’t public. Apple makes about 220 million to 230 million iPhones a year globally, with India’s share of the total increasing rapidly. Apple has accelerated its expansion in the world’s most populous country in recent years, bolstered
A new worry has been rippling across the stock market lately: Entire businesses, not just their employees, might be thrown out of work. While most economists say fears of an artificial intelligence (AI) job apocalypse are overblown, seismic shifts have happened in the past after big tech breakthroughs. The IT revolution of the 1990s led to a surge in productivity that sped up the US economy for several years. It also rendered companies or even industries largely redundant — from travel agents and stockbrokers to classified advertising and newspapers, or video rental stores. Economists expect AI would deliver higher productivity,
RSS